Drug · DIN 02246016
THYROGEN
SINGLE-DOSE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 16, 2025; first marketed August 12, 2002.
- Drug Identification Number (DIN)
- 02246016
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Powder For Solution
- Route
- Intramuscular
- Therapeutic class (ATC)
- Thyrotrophin alfa H01AB01
- Class
- Human
- Record last updated
- August 7, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| THYROTROPIN ALFA | 0.9 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 11, 2024: NOC 33055New Drug Submission (NDS) · Administrative / Administrative Change in Product Ownership
- May 31, 2002: NOC 842New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “thyrogen”. A notice may cover another product or only some lots: read it to see what it covers.
- Thyrogen (thyrotropin alfa for injection): Caution with Preparation and Administration - For Health ProfessionalsDecember 9, 2009 · Biologic or vaccine